Evidence map›Paper›PMID 32663011›Full record

ArticleMolecular pharmaceutics2020

Novel [

Zheng Qiao, Jingli Xu, Rene Gonzalez, Yubin Miao

Open access · greenAbstract read
In one paragraph

Article in Molecular pharmaceutics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.6field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. NovelMolecular pharmaceutics · 2022
    Article
  10. Novel AlBioconjugate chemistry · 2022
    Article
  11. Article
  12. Advances in Receptor-Targeted Radiolabeled Peptides for Melanoma Imaging and Therapy.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2021
    Review
  13. Review
  14. Development and Preclinical Evaluation ofMolecular imaging and biology · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Zheng Qiao
Jingli Xu
Rene Gonzalez
University of Colorado Denver · US

Funding

Novel Receptor-Targeting Peptides for Melanoma TherapyR01CA225837 · NCI · UNIVERSITY OF COLORADO DENVER · PI MIAO, YUBIN · 2018 to 2022
$1.9M
NCI NIH HHS R01 CA225837
6 · The paper itself

Abstract

The purpose of this study was to examine the melanoma targeting and imaging properties of

Indexed as

alpha-MSHAnimalsBiological TransportCell Line, TumorChelating AgentsCyclizationHeterocyclic Compounds, 1-RingKidneyLactamsMelanoma, ExperimentalMiceReceptor, Melanocortin, Type 1TechnetiumTissue Distribution1,4,7-triazacyclononane-N,N',N''-triacetic acidalpha-MSHChelating AgentsHeterocyclic Compounds, 1-RingLactamsReceptor, Melanocortin, Type 1Technetium99mTc(CO)3-NOTA-GGNle-CycMSHhexalpha-melanocyte-stimulating hormonemelanocortin-1 receptormelanoma targetingSPECT

Identifiers

PMID32663011
PMCPMC7484323
OpenAlexW3043071455

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.